News

Public · Published

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

CERo Therapeutics said Fred Hutch Cancer Center in Seattle was activated as a clinical trial site for CERTAIN-T, its ongoing Phase 1 trial of CER-1236 in blood cancers. A University of Washington physician at Fred Hutch will lead the site.

Published:

Updated:

What happened

CERo Therapeutics said Fred Hutch Cancer Center in Seattle was activated as a clinical trial site for CERTAIN-T, its ongoing Phase 1 trial of CER-1236 in blood cancers. A University of Washington physician at Fred Hutch will lead the site.

Confirmed

Global impact / market context

Adding a site can widen where eligible patients are screened and treated, which may speed enrollment for an early-stage study. Faster enrollment gives investors earlier answers on safety and dosing, though this is a research-stage company and no product revenue is described.

Analyst inference

CERo is a small company listed on OTCQB, a lower-tier US market for smaller or earlier-stage firms, so its shares may trade thinly and react sharply to trial news. The update concerns trial operations, not reported efficacy or approval.

Analyst inference

What to watch

  1. The article says six patients were treated in the first two cohorts, and all three patients in the second cohort finished a 28-day dose-limiting toxicity assessment, which means checking for harmful side effects at set doses, without a DLT. Confirmed
  2. Watch whether the new site adds enrolled patients over time, since enrollment speed affects when the company can report the next safety and dosing findings from the Phase 1 study. Analyst inference
  3. Watch for future company updates on the trial as it progresses, including any stated plans for additional cohorts or sites, but treat such plans as proposals until the company confirms they are underway. Proposed

Evidence